February 6 – 10, 2022
Modified Vaccinia Ankara (MVA) virus is a promising viral vector for gene therapy. Several pre-clinical and clinical trials are currently being conducted with MVA as a live vector vaccine against COVID-19, Ebola disease, influenza or various types of cancers. For most applications, a large amount of the vector will be required (>108 infectious virus per dose). High cell concentrations are favorable for developing high-yield MVA vector production systems. Efficient production of MVA in an avian suspension cell line (AGE1.CR.pIX) cultivated in perfusion mode with a membrane-based cell retention system has previously been demonstrated. However, up to now a direct harvest through the membrane for a continuous integrated process was not feasible.
Please click Additional Files below to see the full abstract.
Gwendal Gränicher, Pavel Marichal-Gallardo, Sven Göbel, Masoud Babakhani, Ingo Jordan, Volker Sandig, Yvonne Genzel, and Udo Reichl, "Integrated end-to-end MVA viral vector production: Perfusion culture shows economical advantage over batch culture" in "Advancing Manufacture of Cell and Gene Therapies VII", Sharon Brownlow, Cell & Gene Therapy Catapult, UK; Sean Palecek, University of Wisconsin, USA; Damian Marshall, Achilles Therapeutics, UK; Fernanda Masri, Cell & Gene Therapy Catapult, UK Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/cellgenetherapies_vii/71